Your Health, We Care
Another NameVoranigo、沃拉西德尼、沃拉西地尼
IndicationsIndicated for the treatment of adult and pediatric patients 12 years of age and older with Grade 2 astrocytoma or oligodendroglioma harboring an IDH1 or IDH2 mutation as detected by an FDA-approved te
Specs
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
Vorasidenib is an oral dual inhibitor of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2), and is a targeted therapeutic agent.
Indicated for patients 12 years of age and older with IDH1/2-mutant Grade 2 glioma.
The recommended dosage in adults is 40 mg once daily; in pediatric patients, the dosage is adjusted by body weight (40 mg for ≥40 kg and 20 mg for <40 kg).
Patients of reproductive potential should use effective non-hormonal contraception; in patients with hepatic or renal impairment, monitor for adverse reactions and adjust the dosage as appropriate.
Specific management of overdosage is not explicitly mentioned in the document; use as directed by a physician.
Pharmacokinetic data show that oral absorption is affected by food; it is primarily metabolized by CYP1A2, with a half-life of approximately 10 days.
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
